Chemotherapy: Open Access
Open Access

Abstract

Recurrent Invasive Pulmonary Mucinous Adenocarcinoma Showing Responses to Platinum-Based Chemotherapy Regimens with Docetaxel and Bevacizumab:A Case Report

Jiaqi Chen, Hong Shen, Caixia Dong, Shanshan Weng and Ying Yuan

The primary pulmonary mucinous adenocarcinoma is a rare variety of lung cancer that accounts for 0.24% of all lung cancers [1]. Now it is defined as tumor cells with a goblet or columnar cell morphology with abundant intracytoplasmic mucin [2]. Usually, this type of mucinous neoplasm has specific imaging findings and pathological morphology. And it is often described as a kind of neoplasm is recrudescent rapidly and resistant to radiotherapy and chemotherapy. So this tumor has a remarkably poor prognosis. Recently, some researchers reported that this tumor may have a low rate of EGFR mutation and a high rate of K-ras mutation and ALK rearrangement [3-5].These characteristics of molecular pathology may change the treatment status of the tumor.